Predictive Genetic Testing And Consumer/Wellness Genomics Market By Application (Cancer, Diabetic Screening, Parkinsonism, Cardiovascular, Orthopedic & Musculoskeletal, Nutria Genetics, Skin & Metabolism Genetics), And Trend Analysis From 2013 To 2025

The global predictive genetic testing & consumer/wellness genomics market is anticipated to reach USD 4.6 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers attributing to the market expansion include rising awareness pertaining to the use of genomic tests for the prediction of gene susceptibility for probability of disease development. Genetic data in the ecosystem increases when consumers buy direct-to-consumer genomics products or participate in clinical research trials.

Rising encouragement for the use of these products is anticipated to propel industrial growth. Expansion in the range of consumer genetic tests by market entities is anticipated to fuel progress in the market in the coming years. Introduction of novel platforms anticipates the DNA-powered applications thus rising market penetration.

Moreover, the pharmaceutical companies are also engaged in partnerships with genomics companies in order to develop novel therapeutics on the basis of genotypic and phenotypic correlations. For instance, in April 2016 a ten-year deal was signed between Human Longevity Inc. (HLI) and AstraZeneca, in which HLI is supposed to sequence 500,000 genomes of the clinical trial population of AstraZeneca. This data is to be used for the identification of novel drug targets. The deal also provides AstraZeneca with access to the proprietary knowledgebase in order augment biomarker discovery, and facilitate drug development.

Further Key Findings from the Study Suggest:

Application of genetic susceptibility tests in gynecology and endocrinology, is of great interest thereby resulting to higher adoption.

These tests enable the identification of the susceptibility of genes towards postmenopausal osteoporosis, adenomyosis, and endometriosis.

Breast & ovarian cancer based predictive testing accounted for the largest share owing to the rising use of susceptibility testing for BRCA mutations cancer prediction.

Government and pertinent organizations are engaged in endeavors aimed at curbing cancer-related healthcare expenditure by encouraging patients to undergo regular diagnostic examinations.

CRC screening initiatives undertaken by the governments and implementation of mass CRC screening programs is expected to increase the demand for CRC screening tests.

Asia Pacific is anticipated to witness substantial growth in the coming years owing to accelerated uptake of these predictive tests in the developing economies of this region.

Key players contributing in this market are BGI, Illumina, Inc, Pathway Genomics, Genesis Genetics, 23andMe, Inc, ARUP Laboratories, Color Genomics Inc., and Myriad Genetics, Inc.

These entities are involved in collaborations in order to develop their portfolio with respect to fragmented point-solutions across the genomics value chain.

Table of Contents

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Predictive Genetic Testing & Consumer/Wellness Genomics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Rise in number of novel partnership models
3.1.1.2 Introduction of fragmented point-solutions across the genomics value chain
3.1.1.3 Exponentially decreasing costs for genetic sequencing
3.1.1.4 Introduction of technological advancements in cloud computing and data integration
3.1.2 Market Restraint Analysis
3.1.2.1 Absence of well-defined regulatory framework and low adoption rate
3.1.2.2 Ethical concerns pertaining to implementation
3.2 Penetration & Growth Prospect Mapping for Applications, 2015
3.3 Predictive genetic testing & consumer/wellness genomics-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Test Type Estimates & Trend Analysis
4.1 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Test Types Movement Analysis
4.2 Predictive Testing
4.2.1 Global predictive testing market, 2013 - 2025 (USD Million)
4.2.2 Genetic susceptibility test
4.2.2.1 Global genetic susceptibility test market, 2013 - 2025 (USD Million)
4.2.3 Predictive diagnostics
4.2.3.1 Global predictive diagnostics test market, 2013 - 2025 (USD Million)
4.2.4 Population screening programs
4.2.4.1 Global population screening programs market, 2013 - 2025 (USD Million)
4.3 Consumer Genomics
4.3.1 Global consumer genomics market, 2013 - 2025 (USD Million)
4.4 Wellness Genetics
4.4.1 Global wellness genetics market, 2013 - 2025 (USD Million)
4.4.2 Nutria Genetics
4.4.2.1 Global nutria genetics market, 2013 - 2025 (USD Million)
4.4.3 Skin & Metabolism Genetics
4.4.3.1 Global skin & metabolism genetics market, 2013 - 2025 (USD Million)
4.4.4 Others
4.4.4.1 Global others market, 2013 - 2025 (USD Million)
Chapter 5 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Application Estimates & Trend Analysis
5.1 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Application Movement Analysis
5.2 Breast & Ovarian Cancer Screening
5.2.1 Global breast & ovarian cancer screening market, 2013 - 2025 (USD Million)
5.3 Cardiovascular Screening
5.3.1 Global cardiovascular screening market, 2013 - 2025 (USD Million)
5.4 Diabetic Screening & Monitoring
5.4.1 Global diabetic screening & monitoring market, 2013 - 2025 (USD Million)
5.5 Colon Cancer Screening
5.5.1 Global colon cancer screening market, 2013 - 2025 (USD Million)
5.6 Parkinsonism / Alzheimer’s disease
5.6.1 Global Parkinsonism / Alzheimer’s disease market, 2013 - 2025 (USD Million)
5.7 Urologic Screening/ Prostate Cancer Screening
5.7.1 Global urologic screening/ prostate cancer screening market, 2013 - 2025 (USD Million)
5.8 Orthopedic & Musculoskeletal Screening
5.8.1 Global orthopedic & musculoskeletal screening market, 2013 - 2025 (USD Million)
5.9 Other Cancer Screening
5.9.1 Global other cancer screening market, 2013 - 2025 (USD Million)
5.10 Other Diseases Screening
5.10.2 Global other diseases screening market, 2013 - 2025 (USD Million)
Chapter 6 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Regional Estimates & Trend Analysis, by Test Type & Application
6.1 Predictive Genetic Testing & Consumer/Wellness Genomics Market Share By Region, 2015 & 2025
6.2 North America
6.2.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.3 Europe
6.3.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.3.2 Germany
6.3.2.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.3.3 UK
6.3.3.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.4.3 China
6.4.3.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.4.4 Australia
6.4.4.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.4.5 India
6.4.5.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.4.6 Singapore
6.4.6.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.5 Latin America
6.5.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.6 MEA
6.6.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 Predictive genetic testing & consumer/wellness genomics market, 2013 - 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.2.1 Key Initiatives
7.3 Company Profiles
7.3.1 F. Hoffmann-La Roche Ltd
7.3.1.1 Company overview
7.3.1.1.1 454 Life Sciences (Roche Diagnostics Corporation)
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Abbott (Abbott Diagnostics)
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 Thermo Fisher Scientific, Inc.
7.3.3.1 Company overview
7.3.3.1.1 Affymetrix, Inc.
7.3.3.1.2 Applied Biosystems
7.3.3.2 Financial performance
7.3.3.2.1 Financial performance (Affymetrix)
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Agilent Technologies
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 BGI
7.3.5.1 Company overview
7.3.5.1.1 Complete Genomics Incorporated
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Bio-Rad Laboratories, Inc.
7.3.6.1 Company overview
7.3.6.1.1 GnuBIO, Inc.
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Illumina, Inc.
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 QIAGEN
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic initiatives
7.3.9 Alere
7.3.9.1 Company overview
7.3.9.2 Financial performance
7.3.9.3 Product benchmarking
7.3.9.4 Strategic initiatives
7.3.10 Myriad Genetics, Inc.
7.3.10.1 Company overview
7.3.10.2 Financial performance
7.3.10.3 Product benchmarking
7.3.10.4 Strategic initiatives
7.3.11 Siemens Healthineers
7.3.11.1 Company overview
7.3.11.2 Financial performance
7.3.11.3 Product benchmarking
7.3.11.4 Strategic initiatives
7.3.12 Pathway Genomics
7.3.12.1 Company overview
7.3.12.2 Financial performance
7.3.12.3 Product benchmarking
7.3.12.4 Strategic initiatives
7.3.13 Cooper Surgical, Inc.
7.3.13.1 Company overview
7.3.13.1.1 Genesis Genetics
7.3.13.1.2 Reprogenetics
7.3.13.1.3 Financial performance
7.3.13.1.4 Financial performance
7.3.13.2 Product benchmarking
7.3.13.3 Strategic initiatives
7.3.14 Ambry Genetics Corporation
7.3.14.1 Company overview
7.3.14.2 Financial performance
7.3.14.3 Product benchmarking
7.3.14.4 Strategic initiatives
7.3.15 23andMe, Inc.
7.3.15.1 Company overview
7.3.15.2 Financial performance
7.3.15.3 Product benchmarking
7.3.15.4 Strategic initiatives
7.3.16 Danaher
7.3.16.1 Company overview
7.3.16.1.1 Beckman Coulter, Inc.
7.3.16.2 Financial performance
7.3.16.3 Product benchmarking
7.3.16.4 Strategic initiatives
7.3.17 Cepheid
7.3.17.1 Company overview
7.3.17.2 Financial performance
7.3.17.3 Product benchmarking
7.3.17.4 Strategic initiatives
7.3.18 Hologic, Inc. (Gen-Probe Incorporated)
7.3.18.1 Company overview
7.3.18.2 Financial performance
7.3.18.3 Product benchmarking
7.3.18.4 Strategic initiatives
7.3.19 ARUP Laboratories
7.3.19.1 Company overview
7.3.19.2 Financial performance
7.3.19.3 Product benchmarking
7.3.19.4 Strategic initiatives
7.3.20 GUARDANT HEALTH, INC
7.3.20.1 Company overview
7.3.20.2 Financial performance
7.3.20.3 Product benchmarking
7.3.20.4 Strategic initiatives
7.3.21 Advanced Genomic Solutions (AGS) Ltd
7.3.21.1 Company overview
7.3.21.2 Financial performance
7.3.21.3 Product benchmarking
7.3.21.4 Strategic initiatives
7.3.22 EasyDNA
7.3.22.1 Company overview
7.3.22.2 Financial performance
7.3.22.3 Product benchmarking
7.3.22.4 Strategic initiatives
7.3.23 Color Genomics, Inc.
7.3.23.1 Company overview
7.3.23.2 Financial performance
7.3.23.3 Product benchmarking
7.3.23.4 Strategic initiatives
7.3.24 Counsyl, Inc.
7.3.24.1 Company overview
7.3.24.2 Financial performance
7.3.24.3 Product benchmarking
7.3.24.4 Strategic initiatives
7.3.25 Gene by Gene
7.3.25.1 Company overview
7.3.25.2 Financial performance
7.3.25.3 Product benchmarking
7.3.26 Mapmygenome
7.3.26.1 Company overview
7.3.26.2 Financial performance
7.3.26.3 Product benchmarking
7.3.26.4 Strategic initiatives
7.3.27 Interleukin Genetics Inc.
7.3.27.1 Company overview
7.3.27.2 Financial performance
7.3.27.3 Product benchmarking
7.3.27.4 Strategic initiatives
7.3.28 Laboratory Corporation of America Holdings (LabCorp)
7.3.28.1 Company overview
7.3.28.2 Financial performance
7.3.28.3 Product benchmarking
7.3.28.4 Strategic initiatives
7.3.29 Quest Diagnostics Incorporated
7.3.29.1 Company overview
7.3.29.1.1 Sonora Quest Laboratories
7.3.29.2 Financial performance
7.3.29.2.1 Financial performance
7.3.29.3 Product benchmarking
7.3.29.4 Strategic initiatives
7.3.30 Xcode
7.3.30.1 Company overview
7.3.30.2 Financial performance
7.3.30.3 Product benchmarking
7.3.30.4 Strategic initiatives
7.3.31 Amgen, Inc.
7.3.31.1 Company overview
7.3.31.1.1 deCODE genetics
7.3.31.2 Financial performance (Amgen, Inc.)
7.3.31.3 Product benchmarking